Pertuzumab plus trastuzumab (P+T) in patients (Pts) with colorectal cancer (CRC) with ERBB2 amplification or overexpression: Results from the TAPUR Study

Authors

Ranju Gupta MD, Lehigh Valley Health NetworkFollow
Elizabeth Garret-MayerFollow
Susan HalabiFollow
Pam K. MangatFollow
Stacy D. D'Andre
Eyal Meiri
Sagun ShresthaFollow
Sasha L. WarrenFollow
Shamika RanasingheFollow
Richard L. SchilskyFollow

Publication/Presentation Date

1-2020

Published In/Presented At

Gupta, R., Garrett-Mayer, E., Halabi, S., Mangat, P., D'Andre, S., Meiri, E., Shrestha, S., Warren, S., Ranasinghe, S., & Schilsky, R. (2020, January). Pertuzumab plus trastuzumab (P+T) in patients (Pts) with colorectal cancer (CRC) with ERBB2 amplification or overexpression: Results from the TAPUR Study. Presentation presented at ASCO 2020 Gastrointestinal Cancers Symposium, Virtual.

Disciplines

Medicine and Health Sciences | Oncology

Department(s)

Department of Medicine, Hematology-Medical Oncology Division, Department of Medicine Faculty

Document Type

Presentation